{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-000073","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.421356+00:00","generated_at":"2026-05-16T11:21:24.140393+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zeo partners to commercialize Cytora's oral mucosal stem cell therapy under Florida law","bullets":["Zeo gets exclusive U.S. commercial rights to Cytora's allogeneic oral mucosal stem cell therapy (hOMSC200).","Initial commercialization under Florida SB 1768 for diabetic foot ulcers; estimated 125,000 new patients annually in Florida alone.","Phase 1/2a trial showed favorable safety and statistically significant complete wound closure in 27-month average-open ulcers.","Made Scientific handles GMP manufacturing at Princeton, NJ; Zeo provides market access, distribution, and clinical site management.","Partnership also plans U.S. FDA Phase 2b trial aiming for approved license."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-000073","json":"https://secwatch.observer/filing/0001829126-26-000073.json","markdown":"https://secwatch.observer/filing/0001829126-26-000073.md","text":"https://secwatch.observer/filing/0001829126-26-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912626000073/0001829126-26-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912626000073/zeoscientifix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:21:24.140393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}